Individual trials and meta-analyses have demonstrated that more aggressive treatment with statins, using either more potent drugs or higher doses, results in decreased low-density lipoprotein cholesterol (LDL-C) levels and a further lowering of cardiovascular (CV) event rates when compared with less potent or lower dose statin therapies. [1] [2] [3] [4] [5] [6] Niacin, fibrates, and cholesteryl ester transfer protein inhibitors also alter serum lipid profiles in directions that have been presumed beneficial. When evaluated as adjuncts to aggressive statin therapy in trials designed to assess effects on CV outcomes, these nonstatin agents produced their expected complementary or additive lipid effects but failed to achieve their predicted effects on CV event reduction. [7] [8] [9] Ezetimibe is a nonstatin agent commonly used as an adjunctive therapy in combination with statins to further lower LDL-C. It inhibits the intestinal absorption of cholesterol, leading to an upregulation of LDL receptors in the liver, which results in lowering of LDL-C in the serum. 10 This LDL-C lowering is independent and additive to that of a statin. 11 A large, pooled analysis found that adding ezetimibe to ongoing statin therapy resulted in an average 23.4% further reduction in LDL-C relative to the LDL-C level attained with statin monotherapy before addition of ezetimibe. 12 Furthermore, unlike niacin, fibrates, or cholesteryl ester transfer protein inhibitors when used as an adjunctive therapy, ezetimibe has been shown to augment the effect of statins on lowering of high-sensitivity C-reactive protein. 12 Clinically, the combination of ezetimibe with simvastatin compared with placebo has been shown to reduce first clinical cardiovascular event in patients with aortic stenosis who had no known coronary disease 13, 14 and to reduce a primary composite end point of first major atherosclerotic event (nonfatal myocardial infarction [MI] or coronary death, nonhemorrhagic stroke, or any arterial revascularization procedure) in persons with moderate chronic kidney disease. 15 The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was designed to determine whether adding ezetimibe to simvastatin in patients presenting with acute coronary syndromes (ACS) adds clinical benefit by further reducing major CV events compared with simvastatin monotherapy. 16 The trial design and characteristics of the first 10,000 enrolled patients have been described previously. 16 This article describes the baseline characteristics of the complete cohort enrolled in IMPROVE-IT and discusses the implications of nonstatin-mediated LDL-C reduction and CV risk reduction relating to recent clinical outcomes data.
Methods

Study design and objectives
The design of IMPROVE-IT (ClinicalTrials.gov, NCT00202878) is outlined in Figure 1 . 16 The study enrolled patients within 10 days of ACS hospitalization who had sufficient risk as defined in the protocol (outlined below) and who had an initial LDL-C of ≤125 mg/dL if lipidlowering naive or b100 mg/dL if on a prior prescription lipid-lowering therapy identified as no more potent than simvastatin 40 mg/d. All patients received simvastatin at a starting daily dose of 40 mg and either placebo or 10 mg of ezetimibe added to the baseline simvastatin therapy. The LDL-C entry limitations were set to achieve a mean LDL-C of b70 mg/dL in the simvastatin/placebo cohort, which was the optional recommended target set in the last update of the Adult Treatment Panel III guidelines. 17 The primary end point is CV death, nonfatal MI, nonfatal stroke, rehospitalization for unstable angina (UA), and coronary revascularization (occurring at least 30 days after randomization).
Study population
Initially, the trial enrolled high-risk patients with STsegment elevation MI (STEMI), non-ST-segment elevation MI (NSTEMI), or documented UA who had stable hemodynamics, arrhythmias, and ischemic symptoms and did not require medications known at the time of protocol development in 2004 to interact with simvastatin (see online Appendix). The protocol-specified highrisk characteristics for STEMI were anterior MI or age ≥50 years. The high-risk characteristics for UA/NSTEMI were age ≥50 years and one of the following: ST-segment changes of at least 1 mm, positive cardiac biomarkers, diabetes mellitus, a history of previous MI, a history of coronary artery bypass grafting at least 3 years earlier, or demonstration of at least 2 major coronary arteries with 18 were eligible to be enrolled as well.
Enrollment of STEMI patients was phased out beginning in September 2007 with a second protocol amendment. The STEMI enrollment was limited to minimize any potential effects of lower long-term risk of this population on trial duration (Figure 2 ).
Treatment protocol
The original protocol outlined monitoring of patients' LDL-C levels during the trial and called for their dose of simvastatin to be raised to 80 mg/d if 2 successive LDL-C values exceeded 79 mg/dL. Minimum follow-up was specified to be 2.5 years after the last enrolled patient.
In September 2008, an association between ezetimibe and increased risk for cancer was reported in a trial evaluating the use of simvastatin with ezetimibe on the progress of aortic stenosis (Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] 14 ). To address this concern, a specific cancer-related clinical events committee was formed to provide more detailed cancer-specific data regarding all prevalent and incident cancer cases within IMPROVE-IT to the independent data and safety monitoring board (DSMB) monitoring the trial. The data from this clinical events committee were reviewed by the trial DSMB a total of 7 times between 2008 and the end of the trial with no new safety concerns.
Overall, the protocol has undergone 5 amendments (Table I ). The first 3 of these have been previously described and (1) were related to refinements of the inclusion/exclusion criteria, (2) set the cap on enrollment of STEMI patients, and (3) described the rationale of increasing sample size from an original value of 10,000 to the final value of approximately 18,000. 16 Modeling was used to arrive at this number of patients, which was found to be optimal for preserving study power while minimizing potential issues concerning duration of study follow-up and enrollment. Since 2009, the protocol has undergone 2 additional amendments to accommodate changes to the simvastatin product label and to add a second interim analysis. In June 2011, a Food and Drug Administration (FDA) safety communication restricted the use of 80 mg/d of simvastatin to patients who had been on that dose and stable for 12 months, contraindicated any new starts of simvastatin 80 mg/d, and identified amlodipine and ranolazine as new drugs requiring simvastatin dosage limitations. 19 This communication led to the discontinuation of protocol-directed use of 80 mg/d of simvastatin for (1) patients who had an LDL-C of N79 mg/dL on simvastatin 40 mg/d, (2) patients who had been on simvastatin 80 mg/d for b1 year, or (3) patients who needed to continue either amlodipine or ranolazine. In these 3 groups, the simvastatin dose was restricted or reduced to 40 mg/d. The 40-mg dose was continued rather than reducing it to the FDArecommended limitation of 20 mg/d for patients taking amlodipine or ranolazine based on safety data from this trial. An independent events committee unaware of treatment assignment adjudicated and classified all muscle-related events identified on adverse event and serious adverse event reports using prespecifed criteria described in the protocol. The data from this committee, stratified by treatment assignment, were evaluated in the safety reviews of the DSMB. Patients stable on simvastatin 80 mg/d for ≥1 year were left at that dose per the FDA advisory. These protocol changes and a second interim analysis at 75% of accumulated target events resulted in a combined fourth and fifth amendment to the protocol.
Statistical design and analysis
Key assumptions about sample size and targeted expectations about events included an estimated 1% clinical benefit for every 1.6 mg/dL difference in LDL-C, 1 a 15 mg/dL incremental reduction in LDL-C with ezetimibe treatment, and a 25% discounting of treatment effect in the first 6 months. 16 These assumptions yielded an estimated treatment effect of 9.375% for the primary end point. An independent lipid monitoring committee reviewed on-treatment LDL-C values in the context of the study power assumptions. The committee did not recommend any changes in sample size or trial duration.
There were 3 interim analyses for efficacy during the trial. The original protocol-specified interim analysis at 50% of targeted end points was performed in March 2010 and recommended continuation of the trial. The second DSMB interim analysis at 75% of targeted end points included in the fifth protocol amendment was performed in March 2012. At that time, the DSMB recommended continuation of the trial but requested a third analysis for efficacy, which took place in March 2013 with the same recommendations as after the 2012 analysis. Stopping guidelines for "overwhelming efficacy" were in place from the outset and were based on findings for the primary end point in conjunction with a directionally consistent reduction in total mortality. There were no stopping rules for futility provided to the DSMB for any of Baseline demographic and medical history characteristics are shown in Table II . The median age at randomization was 63 years, with an interquartile range of 56 to 71 years. Most of the patients are male (76%). At randomization, 27% of patients had diabetes, and 21% had experienced a previous MI. The initial event was STEMI in 5,192 (29%), NSTEMI in 8,567 (47%), and UA in 4,385 (24%) patients. Compared with the UA/NSTEMI cohort, the STEMI cohort was younger (median of 60 years vs 64 years) and had lower prevalence of hypertension, diabetes mellitus, and previous MI. Substantially more STEMI patients were not on lipid-lowering therapy at entry (83%) compared with the UA/NSTEMI cohort (60%). Forty-nine percent of the STEMI patients had anterior infarction as a high-risk feature (data not shown). Diabetes (30%) was the most common high-risk feature qualifying patients with UA/NSTEMI, followed by previous MI (26%).
Baseline laboratory findings are also shown in Table II . The trial enrolled patients in the target LDL-C range, and the median high-density lipoprotein cholesterol (HDL-C) level was 40 mg/dL. The median LDL-C level was lower in the UA/NSTEMI cohort compared with the STEMI cohort (93 mg/dL vs 100 mg/dL, P b .001). Renal function was well preserved, with a median serum creatinine of 1.0 mg/dL, and 75% of patients had a calculated creatinine clearance of ≥65 mL/min.
The distributions of baseline lipid levels are shown in Figure 3 . They demonstrate a narrow range of LDL-C levels, as anticipated from the eligibility criteria. Approximately two-thirds of the patients enrolled were naive to lipid-lowering therapy. The lipid-lowering-naive patients had a median LDL-C level that was higher (104 mg/dL) compared with the median LDL-C (80 mg/dL) of those on prior lipid-lowering therapy (data not shown).
Discussion
The IMPROVE-IT trial enrolled patients with selected high-risk criteria after stabilization of a qualifying ACS event who presented with an LDL-C level ≤125 mg/dL. The patients are from countries with different clinical practice patterns and varying social and economic backgrounds, which should make the findings from the trial widely applicable. As expected, the STEMI and UA/NSTEMI ACS populations differ with respect to age and risk factors. The median lipid values for the study population were within expected ranges (LDL-C 95 mg/dL, HDL-C 40 mg/dL, triglycerides 120 mg/dL) given the LDL-C entry criteria. The lower LDL-C and higher triglyceride levels in the UA/NSTEMI population possibly result from differences in previous statin use and in prevalence of diabetes between the 2 populations. The results should provide an evaluation of whether ezetimibe, with its modest estimated incremental reduction in LDL-C of 15 mg/dL in this trial, produces further reduction in CV events in comparison with a simvastatin monotherapy control population targeted to achieve (on average) the Adult Treatment Panel III/European guideline-based goal of b70 mg/dL. 17, 20 The outcome depends on ezetimibe producing the targeted LDL-C difference between treatment arms and this difference having proportionally the same effect on outcomes as would be expected with a statin. Using ezetimibe in addition to a statin produces an average incremental LDL-C reduction of 23% to 24% relative to onstatin LDL-C, an effect similar to that achieved by an 8-fold increase in simvastatin statin dose (ie, 3 dose doublings from 10 to 80 mg). 21 Thus, for the IMPROVE-IT population, where simvastatin monotherapy was designed to achieve a median LDL-C of slightly b70 mg/dL, the addition of ezetimibe should produce the targeted 15 mg/dL difference in LDL-C between the treatment groups. This delta for LDL-C lies at the lower limit of the range of other more intensive statin therapy trials [3] [4] [5] [6] (Table III) . The IMPROVE-IT trial is larger than these previous trials, with longer follow-up (~6 years vs 2-5 years), and will have substantially more primary end points (5,250) than all of these other studies combined. Based on data derived from these and other statin trials included in the Cholesterol Treatment Trialists' meta-analysis 2 (Figure 4) , the incremental outcomes reduction attributable to the between-group difference of 15 mg/dL in LDL-C due to ezetimibe is estimated to fall in the range of 8% to 9%.
A variety of factors could potentially influence the treatment effect of ezetimibe in IMPROVE-IT. First is the assumption that the relationship between LDL-C lowering and CV event lowering with statins will be the same for ezetimibe. The 2 drugs work through final pathways that lead to upregulation of LDL receptors that mediate a complementary reduction in serum LDL-C, and the combination of ezetimibe with ongoing statin augments lowering of C-reactive protein 11, 12 ; however, the incremental efficacy of adding ezetimibe on biomarkers such as carotid intimal thickening and vascular reactivity has been inconsistent, with studies showing beneficial, neutral, and possibly detrimental effects of the drug despite its consistent lowering of LDL-C in those studies. [22] [23] [24] Second, there is question whether the relationship between LDL-C lowering and reduction in CV risk (based on meta-analyses of statin trials 2 ) will remain linear over the entire comparison range of LDL-C being evaluated in IMPROVE-IT. 25 In a post hoc analysis of a similar post-ACS population enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) trial (n = 4,162), 4 an examination of statin-naive patients (n = 2,986) stratified by quartiles of entry LDL-C found the benefit of intensive therapy progressively declined as untreated baseline entry LDL-C decreased. 25 This study suggests that the lower LDL-C entry criteria in IMPROVE-IT compared with PROVE IT (LDL-C limited to ≤125 mg/dL vs no limit, respectively) could make the IMPROVE-IT results more susceptible to any effects of flattening of the relationship between efficacy and LDL-C that may occur at lower LDL-C levels. Interpretation of a separate analysis from PROVE IT, in which cohorts of patients who achieved LDL-C of ≤60 mg/dL were found to have fewer major CV events than cohorts not reaching these levels, 26 suggests that the ezetimibe arm of IMPROVE-IT (with its projected mean achieved LDL-C b55 mg/dL) could have fairly low event rates. These lower rates could help preserve a linear relationship between LDL-C and efficacy at lower levels of achieved LDL-C. Although it is unclear which marker- statin-naive LDL-C at entry or achieved LDL-C-is more important or a better predictor of outcomes, it is certain that the data from IMPROVE-IT will add further insight into the markers' relative importance and that the outcome of IMPROVE-IT could be affected by either. Finally, any relationship between the measured LDL-C difference and measured treatment effect will have to account for possible effects of potential trial-related issues such as withdrawn consent and patient drug discontinuation. For example, in IMPROVE-IT, the median trial duration of almost 6 years, new FDA regulations 19 that required changes in the dosing of simvastatin during the trial, and the 2 negative episodes of publicity surrounding other ezetimibe trials that closed during IMPROVE-IT (re. drug efficacy concerns in the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression [ENHANCE] trial 27 and drug safety concerns of a cancer risk in SEAS 14 ) are all factors that could produce issues with patient drug discontinuation or withdrawal of consent.
The implications of the results from IMPROVE-IT go beyond the specific circumstances of the trial. Although some may question the clinical utility of small treatment effects at low achieved LDL-C levels, the practical value of a positive trial will serve as a definitive proof of concept that LDL-C lowering with compounds other than statins can affect outcomes. The trial may provide support for driving LDL-C to levels below those previously recommended and will raise the issue of whether other molecules-such as PCSK9 antibodies-could have similar proportional benefit as an adjunct to statins. A positive result will also support the concept that ezetimibe can be effective in patients who are unable to tolerate high-dose statins, those who may better tolerate a combination of low-dose statin plus ezetimibe, and those who do not achieve adequate LDL-C lowering despite high-dose statin use. A positive result could also lead to an early re-evaluation of the new American College of Cardiology/American Heart Association cholesterol guidelines that endorse statins as the only recommended drugs for treating cholesterol-related CV risk. 28 If IMPROVE-IT does not meet its primary end point, subsequent analyses evaluating the trial population, drug discontinuations, and assumptions made regarding treatment effects will provide insight into possible trial design issues or mechanistic revelations that could certainly affect beliefs about the "lower is better" hypothesis. Regardless of the outcome with respect to ezetimibe, a trial with 18,144 patients that accumulated 5,250 events and had a mean follow-up time approaching 6 years will add to our understanding of post-ACS and long-term care of atherosclerotic CV disease in current practice.
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